ArticleScientific reports2026
Predictive value of aortic propagation velocity for cardiovascular events in asymptomatic individuals with elevated ASCVD risk.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prediction of cardiovascular diseases (CVD) is a challenge that cardiologists have always faced all the times. Aortic propagation velocity (APV) is an echocardiography index that can be helpful with this regard; however, few studies have addressed the condition. This prospective cohort study was conducted at the outpatient clinic of Imam Reza and Quaem Hospital in Mashhad, Iran. It was conducted on cases with ASCVD score of > 10. All the cases underwent echocardiography and APV was measured for them. The cases were classified into two groups including normal APV (> 56 cm/s) and abnormal APV (≤ 56 cm/s). They were followed for a duration of 1 year and the rate of CVD was compared between the two groups. Moreover, ROC curve analysis was used for determining a cut-off. The primary endpoint was a composite of major adverse cardiovascular events (MACE): non-fatal MI, non-fatal stroke, coronary revascularization, or cardiovascular death. A total of 60 cases, including 37 (61.7%) males and 23 (38.3%) females, were enrolled. After 1 year of follow-up, 7 cases developed MACE: 6 in the abnormal APV group and 1 in the normal APV group (p = 0.039). Logistic regression analysis showed a significant relationship between APV and MACE development (OR = 2.10 per 10 cm/s decrease in APV; 95% CI 1.116-3.932; p = 0.02). ROC curve analysis proposed a cut-off of 49.75 cm/s with a sensitivity of 85.7% and specificity of 60% (AUC = 0.710; 95% CI 0.585-0.835; p = 0.072). Seven cases developed MACE (non-fatal MI, stroke, revascularization, or CV death). APV showed a trend toward prognostic value for MACE, suggesting it may serve as a potential adjunctive marker in this high-risk population; however, larger studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.